RBBP6 induces non‑small cell lung cancer cell proliferation and high expression is associated with poor prognosis

Wang,Qiu‑Shi; Wei,Shi‑Rong; Xiao,Hua‑Liang

doi:10.3892/ol.2020.11403

RBBP6 induces non‑small cell lung cancer cell proliferation and high expression is associated with poor prognosis

Authors:
- Qiu‑Shi Wang
- Shi‑Rong Wei
- Hua‑Liang Xiao
View Affiliations

Affiliations: Department of Pathology, Daping Hospital and Research Institute of Surgery, Army Medical University, Chongqing 400042, P.R. China
Published online on: February 17, 2020 https://doi.org/10.3892/ol.2020.11403
Pages: 2895-2901
Copyright: © Wang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Lung cancer is the most common cause of cancer‑associated mortality in China with 85% of patients having non‑small cell lung cancer (NSCLC). Identifying NSCLC driver genes and prognostic markers is critical to reducing these numbers. The studies of retinoblastoma binding protein 6 (RBBP6) performed on NSCLC is limited. The present study aimed to investigate the molecular function and the prognostic potential of RBBP6 in NSCLC using the A549 cell line and patient samples, respectively. The functional effect on cancer cell proliferation and prognostic value of RBBP6 were examined in vitro and in vivo using reverse transcription‑quantitative PCR, immunofluorescence, immunohistochemistry (IHC) and xenograft implantation. The results demonstrated that RBBP6 mRNA expression was significantly higher in NSCLC tissues compared with in adjacent normal samples. When RBBP6 mRNA expression was interfered with using short hairpin RNA, A549 cell proliferation and xenograft tumor growth were reduced. Additionally, IHC and survival analysis demonstrated that patients with NSCLC with high expression levels of RBBP6 had a shorter median overall survival time compared with patients with low RBBP6 expression (31 vs. 51.5 months), and this was more prominent in stage I‑II patients (43 vs. >67 months). High expression levels of RBBP6 indicated poor prognosis in patients with NSCLC. This may be due to the ability of RBBP6 to promote cancer cell proliferation. RBBP6 may be a potential prognostic biomarker and a therapeutic target for NSCLC.

View Figures

View References

1	Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China, 2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
2	Herbst RS, Morgensztern D and Boshoff C: The biology and management of non-small cell lung cancer. Nature. 553:446–454. 2018. View Article : Google Scholar : PubMed/NCBI
3	Schiller JH: A new standard of care for advanced lung cancer. N Engl J Med. 378:2135–2137. 2018. View Article : Google Scholar : PubMed/NCBI
4	Miller KD, Siegel RL, Lin CC, Mariotto AB, Kramer JL, Rowland JH, Stein KD, Alteri R and Jemal A: Cancer treatment and survivorship statistics, 2016. CA Cancer J Clin. 66:271–289. 2016. View Article : Google Scholar : PubMed/NCBI
5	Pugh DJ, Ab E, Faro A, Lutya PT, Hoffmann E and Rees DJ: DWNN, a novel ubiquitin-like domain, implicates RBBP6 in mRNA processing and ubiquitin-like pathways. BMC Struct Biol. 6:12006. View Article : Google Scholar : PubMed/NCBI
6	Yoshitake Y, Nakatsura T, Monji M, Senju S, Matsuyoshi H, Tsukamoto H, Hosaka S, Komori H, Fukuma D, Ikuta Y, et al: Proliferation potential-related protein, an ideal esophageal cancer antigen for immunotherapy, identified using complementary DNA microarray analysis. Clin Cancer Res. 10:6437–6448. 2004. View Article : Google Scholar : PubMed/NCBI
7	Motadi LR, Bhoola KD and Dlamini Z: Expression and function of retinoblastoma binding protein 6 (RBBP6) in human lung cancer. Immunobiology. 216:1065–1073. 2011. View Article : Google Scholar : PubMed/NCBI
8	Mbita Z, Meyer M, Skepu A, Hosie M, Rees J and Dlamini Z: De-regulation of the RBBP6 isoform 3/DWNN in human cancers. Mol Cell Biochem. 362:249–262. 2012. View Article : Google Scholar : PubMed/NCBI
9	Chibi M, Meyer M, Skepu A, G Rees DJ, Moolman-Smook JC and Pugh DJ: RBBP6 interacts with multifunctional protein YB-1 through its RING finger domain, leading to ubiquitination and proteosomal degradation of YB-1. J Mol Biol. 384:908–916. 2008. View Article : Google Scholar : PubMed/NCBI
10	Chen J, Tang H, Wu Z, Zhou C, Jiang T, Xue Y, Huang G, Yan D and Peng Z: Overexpression of RBBP6, alone or combined with mutant TP53, is predictive of poor prognosis in colon cancer. PLoS One. 8:e665242013. View Article : Google Scholar : PubMed/NCBI
11	Travis WD, Bramblilla E, Müller-Hermelink HK and Harris CC: Tumours of the Lung, Pleura, Thymus and Heart. Pathology and Genetics. World Health Organization (WHO); IARC Press, Lyon: 2004
12	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
13	Yao Z, Fenoglio S, Gao DC, Camiolo M, Stiles B, Lindsted T, Schlederer M, Johns C, Altorki N, Mittal V, et al: TGF-beta IL-6 axis mediates selective and adaptive mechanisms of resistance to molecular targeted therapy in lung cancer. Proc Natl Acad Sci USA. 107:15535–15540. 2010. View Article : Google Scholar : PubMed/NCBI
14	Li L, Luo Q, Xie Z, Li G, Mao C, Liu Y, Wen X, Yin N, Cao J, Wang J, et al: Characterization of the expression of the RNA binding protein eIF4G1 and its clinicopathological correlation with serous ovarian cancer. PLoS One. 11:e01634472016. View Article : Google Scholar : PubMed/NCBI
15	Simons A, Melamed-Bessudo C, Wolkowicz R, Sperling J, Sperling R, Eisenbach L and Rotter V: PACT: Cloning and characterization of a cellular p53 binding protein that interacts with Rb. Oncogene. 14:145–155. 1997. View Article : Google Scholar : PubMed/NCBI
16	Witte MM and Scott RE: The proliferation potential protein-related (P2P-R) gene with domains encoding heterogeneous nuclear ribonucleoprotein association and Rb1 binding shows repressed expression during terminal differentiation. Proc Natl Acad Sci USA. 94:1212–1217. 1997. View Article : Google Scholar : PubMed/NCBI
17	Sakai Y, Saijo M, Coelho K, Kishino T, Niikawa N and Taya Y: cDNA sequence and chromosomal localization of a novel human protein, RBQ-1 (RBBP6), that binds to the retinoblastoma gene product. Genomics. 30:98–101. 1995. View Article : Google Scholar : PubMed/NCBI
18	Moela P, Choene MM and Motadi LR: Silencing RBBP6 (Retinoblastoma Binding Protein 6) sensitises breast cancer cells MCF7 to staurosporine and camptothecin-induced cell death. Immunobiology. 219:593–601. 2014. View Article : Google Scholar : PubMed/NCBI
19	Moela P and Motadi LR: RBBP6: A potential biomarker of apoptosis induction in human cervical cancer cell lines. Onco Targets Ther. 9:4721–4735. 2016. View Article : Google Scholar : PubMed/NCBI
20	Scott RE, Giannakouros T, Gao S and Peidis P: Functional potential of P2P-R: A role in the cell cycle and cell differentiation related to its interactions with proteins that bind to matrix associated regions of DNA? J Cell Biochem. 90:6–12. 2003. View Article : Google Scholar : PubMed/NCBI
21	Dlamini Z, Rupnarain C, Naicker S, Hull R and Mbita Z: Expression analysis and association of RBBP6 with apoptosis in colon cancers. J Mol Histol. 47:169–182. 2016. View Article : Google Scholar : PubMed/NCBI